Reducing the Risk of Pancreatitis by Inhibiting APOC3.

The article discusses the risk of pancreatitis in patients with extreme hypertriglyceridemia and the potential benefits of inhibiting APOC3 to reduce this risk. It highlights the efficacy of plozasiran in lowering plasma APOC3 levels and triglyceride levels, thereby reducing the risk of pancreatitis in patients with familial chylomicronemia syndrome (FCS). The study suggests that targeting APOC3 may be a useful therapy for reducing the risk of high triglyceride levels and pancreatitis in related conditions, such as treatment-refractory MCS. The findings provide evidence that inhibiting APOC3 can effectively reduce the risk of pancreatitis in patients with FCS, offering a promising path forward for managing extreme hypertriglyceridemia and mitigating the risk of pancreatitis. [Extracted from the article]